Repression of β-catenin signaling by PPARγ ligands

European Journal of Pharmacology

Volumn 636, Issue 1-3, 2010, Pages 198-202

  Lu, Desheng ^a   Carson, Dennis A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Catenin; GW1929 (N (2 Benzoylphenyl) O 2 (methyl 2 pyridinylamino)ethyl l tyrosine hydrochloride); PPAR ; Rosiglitazone; Troglitazone

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BETA CATENIN; G 3335; LEUCINE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PSEUDOLARIC ACID B; ROSIGLITAZONE; T CELL FACTOR PROTEIN; TETRADECYLTHIOACETIC ACID; TOMELUKAST; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LEF; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

BETA CATENIN; CELL LINE; GENES, REPORTER; HUMANS; LIGANDS; MEDIATOR COMPLEX SUBUNIT 1; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 77952669603     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.010     Document Type: Article

References (29)

1. Altiok S., Xu M., Spiegelman B.M. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997, 11:1987-1998.
2. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
3. Crawford H.C., Fingleton B.M., Rudolph-Owen L.A., Goss K.J., Rubinfeld B., Polakis P., Matrisian L.M. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999, 18:2883-2891.
4. Debril M.B., Renaud J.P., Fajas L., Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J. Mol. Med. 2001, 79:30-47. (Berlin, Germany).
5. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
6. Girnun G.D., Smith W.M., Drori S., Sarraf P., Mueller E., Eng C., Nambiar P., Rosenberg D.W., Bronson R.T., Edelmann W., Kucherlapati R., Gonzalez F.J., Spiegelman B.M. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc. Natl. Acad. Sci. USA 2002, 99:13,771-13,776.
7. Grommes C., Landreth G.E., Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004, 5:419-429.
8. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512. (New York, N.Y).
9. Jansson E.A., Are A., Greicius G., Kuo I.C., Kelly D., Arulampalam V., Pettersson S. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102:1460-1465.
10. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819.
11. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA 1997, 94:4318-4323.
12. Kliewer S.A., Xu H.E., Lambert M.H., Willson T.M. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 2001, 56:239-263.
13. Koeffler H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 2003, 9:1-9.
14. Koga H., Sakisaka S., Harada M., Takagi T., Hanada S., Taniguchi E., Kawaguchi T., Sasatomi K., Kimura R., Hashimoto O., Ueno T., Yano H., Kojiro M., Sata M. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001, 33:1087-1097. (BaltimoreMd).
15. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12,953-12,956.
16. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
17. Li M., Pascual G., Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 2000, 20:4699-4707.
18. Liu J., Wang H., Zuo Y., Farmer S.R. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol. Cell. Biol. 2006, 26:5827-5837.
19. Lu D., Zhao Y., Tawatao R., Cottam H.B., Sen M., Leoni L.M., Kipps T.J., Corr M., Carson D.A. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2004, 101:3118-3123.
20. Lu D., Cottam H.B., Corr M., Carson D.A. Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. USA 2005, 102:18,567-18,571.
21. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 2004, 5:691-701.
22. Nusse R. Wnt signaling in disease and in development. Cell Res. 2005, 15:28-32.
23. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
24. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
25. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., Dubuquoy L., Bac P., Champy M.F., Plunket K.D., Leesnitzer L.M., Blanchard S.G., Desreumaux P., Moras D., Renaud J.P., Auwerx J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 2001, 8:737-747.
26. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 1999, 96:5522-5527.
27. Wang C., Fu M., D'Amico M., Albanese C., Zhou J.N., Brownlee M., Lisanti M.P., Chatterjee V.K., Lazar M.A., Pestell R.G. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol. Cell. Biol. 2001, 21:3057-3070.
28. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., Glass C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. USA 2003, 100:6712-6717.
29. Xiao J.H., Ghosn C., Hinchman C., Forbes C., Wang J., Snider N., Cordrey A., Zhao Y., Chandraratna R.A. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J. Biol. Chem. 2003, 278:29,954-29,962.